Evofem Biosciences Inc.’s (NASDAQ:EVFM) Non-Hormonal Phexxi Vaginal Gel For Pregnancy Prevention Receives FDA Approval

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Evofem Biosciences Inc. (NASDAQ:EVFM) has announced that the FDA has approved its Phexxi vaginal gel comprising of potassium bitartrate, citric acid, and lactic acid for pregnancy prevention in women. The gel is used in females of reproductive potential as an on-demand contraceptive method.

Evofem’s new Phexxi vaginal gel makes vagina acidic and inhospitable for sperms

The gel will be the first on-demand, non-hormonal vaginal pH regulator method of contraception that has been designed to keep vaginal pH within a range of 3.5 to 4.5. This is an acidic environment that is not ideal for sperm cells to thrive.

Michael Thomas, the Obstetrics and Gynaecology Department heat at College of Medicine at the University of Cincinnati, indicated that in the last two decades, there have been fewer advances in contraceptives and now Phexxi represents a huge milestone in the health of women. He added that most women have been cycling from one contraceptive to another but have not found one that is right for reproductive and sexual needs.

Thomas stated that the vaginal gel now will offer women options away from hormones as well as give them a choice on how they can prevent pregnancy. He indicated that he is looking forward to prescribing Phexxi for his patients.

Evofem to launch the vaginal gel in September

Evofem plans to launch the gel in September with the Phexxi Concierge Experience, a comprehensive healthcare provider and patient support system. It is a robust offering meant to offer physicians n-demand educational support as well as quick and simple access for women to Phexxi. It will enable women to secure prescriptions, receive counseling assistance as well as determine insurance coverage and out of pocket costs.

The CEO of Evofem Saundra Pelletier indicated that the Phexxi approval by the FDA means that women seeking non-hormonal contraceptive alternatives can now access that. They will be able to control when to use it under their terms. He added that they were delighted to deliver this innovation for women in a group ready for change.